This Swedish competence center develops technologies and systems amenable to scale-up to support commercial bioproduction, using intensification such as continuous bioprocessing, among others, and including emerging cell and gene therapy platforms. AdBIOPRO projects addresses optimization, new equipment, process analytical technology PAT and methods for bioprocessing based on mammalian/human cells, including continuous perfusion process and continuous purification process, for the production of biopharmaceuticals, cells as product and viral vector, adeno-associated virus and lentivirus for gene therapy.

Continuous bioprocesses has a small footprint in comparison with legacy fed-batch processes, with lower capital expenditure and potentially higher sustainability from lower energy demand. Continuous medium renewal in perfusion operation gives a better cell health, control of the product quality (encouraged by health authorities) and is amenable to single-use equipment, providing flexibility of capacity and process transfer.

Coordinator: KTH

Partners: KTH Royal Institute of Technology, Lund University, Karolinska Hospital, Karolinska Institutet and Linköping University, Alfa Laval, ArgusEye, AstraZeneca, BioInvent International, BioLamina, Cellcolabs, Cellevate, Cytiva, Erbi Biosystems, a company of Merck KGaA Darmstadt Germany, Magic Bioprocessing, Metenova, NorthX Biologics, Nyctea Technologies, TimeGate Instruments, Valneva and XNK Therapeutics.


  • WP1 – New technologies and applications for the production of glycoprotein
  • WP2 – Modelling and control of the culture processes
  • WP3 – Purification bioprocessing for the production of adeno-associated virus and lentivirus
  • WP4 – Culture bioprocessing for the production of adeno-associated virus and lentivirus
  • WP5 – Culture bioprocessing for the production cells as product

Contact: Veronique Chotteau


Funding authority: VINNOVA, Sweden